18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma

被引:0
|
作者
Luo, Zhe-Huang [1 ]
Luo, Xiao-Yan [2 ]
Qi, Wan-Ling [1 ]
Liu, Qian [3 ]
机构
[1] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Affiliated Hosp 1, Dept Nucl Med, Nanchang, Peoples R China
[2] Jiangxi Prov Childrens Hosp, Affiliated Childrens Hosp, Dept Clin Lab, Nanchang Med Coll, Nanchang, Peoples R China
[3] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Affiliated Hosp 1, Dept Pathol, Nanchang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
pulmonary sarcomatoid carcinoma; fluorodeoxyglucose; positron emission tomography/computed tomography; imaging features; TTF-1; expression; RESECTION;
D O I
10.3389/fonc.2024.1334156
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
<bold>Background:</bold> Pulmonary sarcomatoid carcinoma (PSC) is a rare highly aggressive and poorly differentiated non-small cell carcinoma, and little is known about the information on the usefulness of F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT). We investigated the clinical and F-18-FDG PET/CT features of PSC. <bold>Methods:</bold> We retrospectively analyzed 25 consecutive PSC patients who had undergone F-18-FDG PET/CT. Demographic data, PET/CT findings before treatment, pathological features, and prognosis in these patients were investigated to define correlates between maximal standard uptake value (SUVmax) and clinicopathological parameters. <bold>Results:</bold> From March 2017 to January 2023, twenty-five eligible patients with PSC were identified. There were 23 (92%) men, aged 68.5 +/- 8.5 (range 56-90) years. Eighteen (72%) patients had a frequent smoking history. The mean size of PSCs was 59.3 +/- 18.6 (range 29-97) mm, and 23 (92%) PSCs were Stage IV tumors. 20 (80%) lesions were located in the upper lung and 19 (76%) cases belonged to the peripheral type. Necrotic foci appeared in 21(84%) tumors. 11 (44%) PSCs invaded the pleura. All PSCs were FDG avid, and the mean of SUVmax was 11.8 +/- 5.3 (range 4.8-25.5). Metastases were found on PET/CT in 24(96%) patients. The SUVmax of the lesions >= 5cm was higher than that of the lesions < 5cm (p=0.004), and the SUVmax of lesions with TTF-1 expression was higher than those of lesions without TTF-1 expression (p=0.009). All of the 25 primary lesions were considered malignant and confirmative, probable, and possible diagnosis of PSC was made in 2 (8%), 4 (16%), and 5(20%) patients, respectively on PET/CT. PSC was not considered in 14 (56%) patients, in PET/CT. The survival of patients with surgery didn't demonstrate a significantly good prognosis as compared with those without surgery (p=0.675). <bold>Conclusion:</bold> All PSCs had obvious FDG avidity. Although imaging diagnosis is still difficult, combined clinical and imaging features more than 40% of primary lesions were considered for the possibility of PSC in our group. Early histopathological diagnosis is necessary to help develop a reasonable regimen.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer
    Roop, Mohan J.
    Singh, Baljinder
    Singh, Harmandeep
    Watts, Ankit
    Kohli, Pavneet S.
    Mittal, Bhagwant R.
    Singh, Gurpreet
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (05) : 335 - 340
  • [42] Value of 18F-FDG PET/CT in patients with hepatic metastatic carcinoma of unknown primary
    Li, Yuekai
    Li, Fengcai
    Li, Xin
    Qu, Lili
    Han, Jiankui
    MEDICINE, 2020, 99 (50) : E23210
  • [43] SUVmax as Predictor of Metastatic Disease on 18F-FDG PET-CT in Hepatocellular Carcinoma
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2024, 34 (04): : 394 - 399
  • [44] Clinical impact of 18F-FDG PET/CT in the pretreatment evaluation of patients with locally advanced cervical carcinoma
    Akkas, Burcu E.
    Demirel, Busra B.
    Vural, Gulin U.
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (10) : 1081 - 1088
  • [45] Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma
    Xie, Peng
    Yue, Jin-Bo
    Zhao, Han-xi
    Sun, Xin-Dong
    Kong, Li
    Fu, Zheng
    Yu, Jin-Ming
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (06) : 883 - 889
  • [46] Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials
    Graham, Michael M.
    Wahl, Richard L.
    Hoffman, John M.
    Yap, Jeffrey T.
    Sunderland, John J.
    Boellaard, Ronald
    Perlman, Eric S.
    Kinahan, Paul E.
    Christian, Paul E.
    Hoekstra, Otto S.
    Dorfman, Gary S.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) : 955 - 961
  • [47] 18F-FDG PET/CT Imaging for Mixed Germ Cell Tumor in the Pineal Region
    Park, Soon-Ah
    Kim, Tae Young
    Choi, See-Sung
    Yang, Chung-Yong
    Kim, Hun Soo
    Choi, Keum Ha
    CLINICAL NUCLEAR MEDICINE, 2012, 37 (03) : E61 - E63
  • [48] Advancing the diagnosis of epithelioid hemangioendothelioma by 18F-FDG PET/CT
    Wei, Weijun
    Huang, Gang
    Liu, Jianjun
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 11 (03): : 207 - 209
  • [49] Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer
    Yang, Wenfeng
    Zhang, Yongming
    Fu, Zheng
    Yu, Jinming
    Sun, Xiaorong
    Mu, Dianbin
    Han, Anqin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (07) : 1291 - 1299
  • [50] 18F-Fluciclovine PET/MRI in a Patient With Squamous Cell Carcinoma of the Uterine Cervix Correlated With 18F-FDG PET/CT
    Nguyen, Nghi C.
    Moon, Chan Hong
    Beriwal, Sushil
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (10) : 802 - 804